Navigate
X
    QualityStocks
  • 18 years ago

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is focused on the development of specialty therapeutics for gastrointestinal and endocrine disorders. Currently, the company is progressing two late-stage programs: GATTEX™ (teduglutide), which is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection), which is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. For further information, visit the Company’s web site at www.npsp.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…